When Trials Can’t Go Virtual: Conducting Phase 1 Clinical Trials During the COVID-19 Pandemic, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will draw upon experience gained, conducting Phase 1 trials at their clinical pharmacology unit in order to present a stepwise approach for executing trials during the COVID-19 pandemic. The speakers will explain their process for establishing a validated COVID-19 testing platform and implementing safety measures to protect participants and staff in extensive detail. Attendees will be presented with case studies and data generated from trials that have been conducted since April 2020 at a dedicated Phase 1 unit located in Cypress, CA.

Xtalks Life Science Webinars

A Phase 1 service provider must modify their work procedures and reconfigure the clinical pharmacology unit in a manner which protects both study participants and clinical operations personnel.

The onset of the COVID-19 pandemic has accelerated the adoption of “virtual” clinical trials by the drug development industry, also requiring service providers to quickly pivot their offerings to one which emphasizes conducting trials in this manner instead of traditional models. In just a short period of time, companies have changed the way they do business, encouraging options for conducting virtual trials such as: e-consenting, remote monitoring, telemedicine and at-home visits. However, several trials carried out during Phase 1 through Phase 4 of a clinical development plan still require “hands-on” clinical trial provider contact with the study participant in either an in-patient or out-patient setting.

This webinar will primarily focus on the management of study volunteers participating in Early Clinical Development (Phase I) clinical trials. In order to gain confidence from Investigational Review Boards and study sponsors to proceed with a trial safely during the COVID-19 pandemic, a Phase 1 service provider must modify their work procedures and reconfigure the clinical pharmacology unit in a manner which protects both study participants and clinical operations personnel.

In this webinar, WCCT Global, a CRO dedicated to Early Clinical Development, will draw upon experience gained within its Phase 1 clinical pharmacology unit in order to present a stepwise approach for conducting trials under these conditions. WCCT will also review case studies and data generated from trials that have been conducted at its clinical pharmacology unit in Cypress, CA.

Join Mel Affrime, PharmD, President & Chief Scientific Officer, WCCT Global and David Nguyen, MD, MBA, Chief Medical and Operations Officer, WCCT Global in a live webinar on Tuesday, October 20, 2020 at 2pm EDT.

For more information or to register for this event, visit When Trials Can’t Go Virtual: Conducting Phase 1 Clinical Trials During the COVID-19 Pandemic.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website